Transplant outcomes in leukodystrophies

Seminars in Hematology
P J Orchard, J Tolar

Abstract

Hematopoietic stem cell transplantation (HSCT) has been used for three decades as therapy for lysosomal storage diseases. Stable engraftment following transplantation has the potential to provide a source of an enzyme for the life of a patient. Recombinant enzyme is available for disorders that do not have a primary neurologic component. However, for diseases affecting the central nervous system (CNS), intravenous enzyme is ineffective due to its inability to cross the blood-brain barrier. For selected lysosomal disorders, including metachromatic leukodystrophy and globoid cell leukodystrophy, disease phenotype and the extent of disease at the time of transplantation are of fundamental importance in determining outcomes. Adrenoleukodystrophy is an X-linked, peroxisomal disorder, and in approximately 40% of cases a progressive, inflammatory condition develops in the CNS. Early in the course of the disease, allogeneic transplantation can arrest the disease process in cerebral adrenoleukodystrophy, while more advanced patients do poorly. In many of these cases, the utilization of cord blood grafts allows expedient transplantation, which can be critical in achieving optimal outcomes.

References

Apr 1, 1976·Journal of Neurochemistry·M IgarashiK Suzuki
Jan 4, 1990·The New England Journal of Medicine·W KrivitN K Ramsay
Oct 3, 1981·Lancet·J R Hobbs
Apr 15, 1983·Biochemical and Biophysical Research Communications·A L FluhartyH Kihara
Jan 1, 1984·Human Genetics·B Herz, G Bach
Nov 1, 1984·Neurology·H W MoserC L White
Sep 1, 1995·Journal of Neuropathology and Experimental Neurology·H W Moser
Jan 1, 1993·Journal of Inherited Metabolic Disease·J Aicardi
Jan 1, 1994·Human Mutation·V GieselmannC P Morris
Oct 1, 1995·Human Molecular Genetics·N TatsumiM Taniike
Aug 19, 1997·Proceedings of the National Academy of Sciences of the United States of America·J F LuK D Smith
Apr 17, 1998·The New England Journal of Medicine·W KrivitL A Lockman
May 2, 2001·Cell Biochemistry and Biophysics·T YamadaT Kobayashi
May 24, 2001·Current Opinion in Neurology·J BergerS Forss-Petter
Mar 7, 2003·Bone Marrow Transplantation·C PetersUNKNOWN Working Party on Inborn Errors, European Bone Marrow Transplant Group
Nov 25, 2005·Pediatric Transplantation·Asif MahmoodAnn Moser
Dec 2, 2005·Journal of Neuropathology and Experimental Neurology·James M PowersKirby D Smith
Dec 29, 2005·JAMA : the Journal of the American Medical Association·Hugo W MoserPrachi Dubey
Apr 8, 2006·Molecular Genetics and Metabolism·Peter J MeikleJohn J Hopwood
Jun 10, 2006·Journal of Inherited Metabolic Disease·Jaap Jan Boelens
Feb 10, 2007·Bone Marrow Transplantation·J TolarL Charnas
Sep 25, 2007·The Journal of Pediatrics·Paul J OrchardJakub Tolar
Sep 25, 2007·Journal of Child Neurology·Maria GörgAlfried Kohlschütter
Oct 2, 2007·Pediatric Neurology·Florian Eichler, Keith Van Haren
May 28, 2008·Acta Paediatrica. Supplement·Volkmar Gieselmann
Mar 18, 2008·Journal of Inherited Metabolic Disease·F SedelO Lyon-Caen
Jun 24, 2008·Annals of Neurology·Florian S EichlerRichard M Ransohoff
Jul 18, 2008·Human Molecular Genetics·Steven A GoldmanMartha S Windrem
Nov 26, 2008·Bone Marrow Transplantation·A BiffiM Sessa
Dec 11, 2008·Annals of Neurology·Tyler Mark PiersonGihan I Tennekoon
Mar 24, 2009·Pediatric Neurology·Patricia K DuffnerMelissa P Wasserstein
Apr 7, 2009·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Patricia K DuffnerChester Whitley

❮ Previous
Next ❯

Citations

Aug 24, 2013·Drug Design, Development and Therapy·Shilpa A Patil, Gustavo H B Maegawa
Aug 3, 2014·Pediatrics in Review·Tammy I KangChris Feudtner
May 10, 2011·Expert Opinion on Biological Therapy·Angela Gritti
Jun 19, 2010·Expert Opinion on Emerging Drugs·Michael Beck
Mar 14, 2013·Expert Opinion on Medical Diagnostics·Sakkubai Naidu, Doris D M Lin
Aug 21, 2013·Pediatric Neurology·Cameron J BrimleyJoshua L Bonkowsky
Feb 19, 2013·Translational Research : the Journal of Laboratory and Clinical Medicine·Jakub Tolar
Jun 29, 2011·Developmental Medicine and Child Neurology·Alfried Kohlschütter
Sep 28, 2010·American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics·Orna Staretz-ChachamEllen Sidransky
Jun 24, 2014·Annals of Clinical and Translational Neurology·Holly M AndersonJoshua L Bonkowsky
Oct 17, 2012·The Journal of Pediatrics·Clint NelsonJoshua L Bonkowsky
May 14, 2016·Experimental Neurology·M Joana Osorio, Steven A Goldman
Feb 5, 2016·Genetics in Medicine : Official Journal of the American College of Medical Genetics·David P Dimmock
Sep 12, 2018·Journal of Child Neurology·Paul J Orchard
May 2, 2012·Current Opinion in Neurology·Donatella De FeoGianvito Martino
Apr 1, 2010·Continuum : Lifelong Learning in Neurology·Gregory M Pastores
Oct 1, 2011·Expert Review of Neurotherapeutics·Alfried Kohlschütter, Florian Eichler
Nov 21, 2012·International Journal of Molecular Medicine·Giancarlo ParentiMariacarolina Salerno
May 19, 2019·Transplant Infectious Disease : an Official Journal of the Transplantation Society·Eman F BoteinAli M Shaltot
Nov 7, 2019·Orphanet Journal of Rare Diseases·Shanice BeerepootNicole I Wolf
May 5, 2021·Lipids in Health and Disease·Muna Abed RabboJohnny Stiban

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Adrenoleukodystrophy

Adrenoleukodystrophy (ALD), the most frequent peroxisomal disorder, is an X-linked disorder caused by a defect in the metabolism of long chain fatty acids leading to demyelination, neurodegeneration, and death. Here is the latest research.

Blood Brain Barrier & Cytokines

Some cytokines are able to cross the blood brain barrier through transport systems and enter the cerebrospinal fluid and interstitial fluid spaces. Here is the latest research on cytokines crossing the blood brain barrier and how this can affect tissues within the CNS.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.